fig3

Inflammation-targeted nanomedicines for atherosclerotic cardiovascular disease: from atherosclerosis regression to post-myocardial infarction management

Figure 3. Inflammation-guided targeting and responsive delivery strategies for atherosclerosis. (A) Ligand-mediated targeting: CFNs recognize P-selectin on activated endothelium. Adapted with permission from Ref.[36]. Licensed under CC BY 4.0; (B) pH-responsive theranostic delivery. Acid-triggered hydrolysis of benzoic-imine linkers induces disassembly of ST/NCP-PEG, releasing simvastatin and Gd complexes for anti-inflammatory therapy and enhanced T1-weighted MRI. Adapted with permission from Ref.[39]. Licensed under CC BY 4.0; (C) Biomimetic targeting: MM/RAPNPs use membrane-associated integrin α4β1 to interact with endothelial VCAM-1, promoting nanoparticle accumulation in atherosclerotic plaques. Adapted with permission from Ref.[40]. Licensed under CC BY 4.0. CFNs: Fucoidan–chitosan nanoparticles; ST/NCP-PEG: simvastatin-loaded, PEGylated lipid-coated nanoscale coordination polymer nanoparticles; MRI: magnetic resonance imaging; PLGA: poly(lactic-co-glycolic acid); MM/RAPNPs: macrophage membrane-coated, rapamycin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles; VCAM-1: vascular cell adhesion molecule-1; RAP: rapamycin.